An experimental biotech treatment for the chronic immune disorder psoriasis eliminated red, scaly skin patches more than the leading biologic treatment for moderate-to-severe cases, researchers reported Thursday.
The study by Johnson & Johnson's biotech unit, Centocor Inc., is the first head-to-head comparison of biologic drugs in psoriasis patients, the company said.
Several such drugs _ complex treatments manufactured by living cells _ have come on the market since 2003 for psoriasis and other conditions caused by faulty immune systems, but their high cost, need to be injected and risk of serious infections have somewhat limited their use.
…
No comments:
Post a Comment